Analysts forecast that MEDNAX Inc (NYSE:MD) will report $911.91 million in sales for the current quarter, Zacks reports. Nine analysts have provided estimates for MEDNAX’s earnings. The highest sales estimate is $926.60 million and the lowest is $897.74 million. MEDNAX posted sales of $842.94 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 8.2%. The business is expected to report its next quarterly earnings report on Friday, July 27th.
According to Zacks, analysts expect that MEDNAX will report full year sales of $3.71 billion for the current financial year, with estimates ranging from $3.66 billion to $3.75 billion. For the next year, analysts anticipate that the firm will post sales of $3.95 billion per share, with estimates ranging from $3.87 billion to $4.06 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that that provide coverage for MEDNAX.
MEDNAX (NYSE:MD) last posted its quarterly earnings data on Monday, April 30th. The company reported $0.89 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.82 by $0.07. The business had revenue of $901.90 million for the quarter, compared to analysts’ expectations of $903.75 million. MEDNAX had a return on equity of 10.13% and a net margin of 9.34%. The business’s revenue was up 7.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.75 EPS.
Several analysts have weighed in on the company. Credit Suisse Group cut their price objective on MEDNAX to $57.00 and set a “neutral” rating on the stock in a research report on Monday, May 7th. Zacks Investment Research raised MEDNAX from a “sell” rating to a “hold” rating in a research report on Saturday, May 5th. Citigroup cut their price objective on MEDNAX from $57.00 to $50.00 and set a “neutral” rating on the stock in a research report on Friday, May 4th. ValuEngine cut MEDNAX from a “sell” rating to a “strong sell” rating in a research report on Wednesday, May 2nd. Finally, TheStreet cut MEDNAX from a “b” rating to a “c” rating in a research report on Monday, April 23rd. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the stock. MEDNAX presently has a consensus rating of “Hold” and an average price target of $55.92.
In other news, SVP Dominic J. Andreano sold 18,000 shares of MEDNAX stock in a transaction that occurred on Monday, June 11th. The shares were sold at an average price of $46.95, for a total transaction of $845,100.00. Following the completion of the transaction, the senior vice president now directly owns 24,896 shares in the company, valued at $1,168,867.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David A. Clark sold 11,607 shares of the business’s stock in a transaction that occurred on Friday, June 1st. The stock was sold at an average price of $45.15, for a total transaction of $524,056.05. Following the completion of the transaction, the insider now owns 32,845 shares of the company’s stock, valued at $1,482,951.75. The disclosure for this sale can be found here. Insiders have sold 75,251 shares of company stock valued at $3,462,384 over the last quarter. Company insiders own 2.40% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Principal Financial Group Inc. raised its holdings in MEDNAX by 2.8% in the 1st quarter. Principal Financial Group Inc. now owns 408,927 shares of the company’s stock worth $22,748,000 after acquiring an additional 11,154 shares during the last quarter. Summit Trail Advisors LLC raised its holdings in MEDNAX by 2,817.3% in the 1st quarter. Summit Trail Advisors LLC now owns 103,564 shares of the company’s stock worth $104,000 after acquiring an additional 100,014 shares during the last quarter. Xact Kapitalforvaltning AB raised its holdings in MEDNAX by 39.3% in the 1st quarter. Xact Kapitalforvaltning AB now owns 12,400 shares of the company’s stock worth $690,000 after acquiring an additional 3,500 shares during the last quarter. Royal Bank of Canada raised its holdings in MEDNAX by 27.2% in the 1st quarter. Royal Bank of Canada now owns 40,603 shares of the company’s stock worth $2,259,000 after acquiring an additional 8,692 shares during the last quarter. Finally, Legal & General Group Plc raised its holdings in MEDNAX by 16.4% in the 1st quarter. Legal & General Group Plc now owns 137,616 shares of the company’s stock worth $7,655,000 after acquiring an additional 19,421 shares during the last quarter. Institutional investors own 97.02% of the company’s stock.
MEDNAX opened at $44.97 on Friday, Marketbeat reports. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.63. The company has a market cap of $4.26 billion, a price-to-earnings ratio of 14.28, a PEG ratio of 1.15 and a beta of 0.24. MEDNAX has a fifty-two week low of $40.56 and a fifty-two week high of $63.04.
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
Get a free copy of the Zacks research report on MEDNAX (MD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.